Business
Medicure Reports Financial Results for the Year Ended December 31, 2025 and Schedules April 27, 2026 Conference Call
WINNIPEG, MB / ACCESS Newswire / April 23, 2026 / Medicure Inc. (" Medicure " or the " Company...
About this update from Medicure Inc.
[{"type":"text","content":"Medicure Reports Financial Results for the Year Ended December 31, 2025 and Schedules April 27, 2026 Conference CallWINNIPEG, MB / ACCESS Newswire / April 23, 2026 / Medicure Inc. (\"Medicure\" or the \"Company\") (TSXV:MPH)(OTC:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today reported its results from operations for the year ended December 31, 2025 and will have a conference call to present the Financial Results on April 27, 2026 at 8:30 am Eastern Time.Quarter and Year Ended December 31, 2025 Highlights:Recorded total net revenue of $28.9 million during the year ended December 31, 2025 compared to $21.9 million for the year ended December 31, 2024;Recorded total net revenue of $8.5 million during the quarter ended December 31, 2025 compared to $5.9 million for the quarter ended December 31, 2024;Recorded total net revenue from the sale of AGGRASTAT® of $5.7 million during the year ended December 31, 2025 compared to $8.1 million for the year ended December 31, 2024;The Pharmacy Business Segment, which includes Marley Drug, and the Company's two newly acquired pharmacies (purchased in 2025), Gateway Medical Pharmacy and West Olympia Pharmacy, recorded total net revenue of $20.3 million ($3.7 million from sales of ZYPITAMAG®, and $16.6 million from other pharmacy revenue) during the year ended December 31, 2025 compared to net revenue from the Marley Drug business of $10.8 million ($3.2 million from sales of ZYPITAMAG® , and $7.6 million from other pharmacy revenue) for the year ended December 31, 2024;Recorded total net revenue from the sale of ZYPITAMAG® of $6.5 million ($2.8 million through the traditional insured channels, and $3.7 million through Marley Drug) during the year ended December 31, 2025 compared to $6.2 million ($3.0 million through the traditional insured channels, and $3.2 million through Marley Drug) for the year ended December 31, 2024;Medicure invested $3.2 million in research and development during the year ended December 31, 2025, underscoring its commitment to advancing innovative therapies, such as the Phase 3 trial of Medicure's investigational product MC-1 for the treatment of PNPO deficiency and delivering long-term value to patients and shareholders;Adjuste...